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Summary 
Familial cutaneous mastocytosis is an exceptional condition of unknown etiology. In this 
study we report the largest series of patients with familial cutaneous mastocytosis without 
other manifestations (18 affected subjects from seven unrelated families), and we 
investigate the role of germ-line KIT mutations in the pathogenesis of the disease. The mean 
age at onset was 5.4 years (range from birth to 22 years), and the clinical behavior was 
variable over a mean follow up period of 15.1 years (range 2-36): improvement in seven, 
stability in eight and worsening in the remaining three patients. The pattern of inheritance 
was compatible with an autosomal dominant trait with incomplete penetrance; a female 
preponderance (14 females vs 4 males, ratio 3.5:1) was noted; among the six women who 
have been pregnant at least once, three experienced important clinical changes during 
pregnancy. No germ-line mutation was found in the exons 10, 11, and 17 of the KIT proto-
oncogene, which are the most commonly mutated exons in sporadic mastocytosis. However, 
in the majority of affected subjects we found the Met541Leu polymorphic variant of the KIT 
gene, which seems to confer a growth advantage to mast cells in vitro. This observation 
further suggests that the Met541Leu may be a predisposing factor of cutaneous 
mastocytosis, although it seems to be neither necessary nor sufficient for the development of 
the disease.  
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Introduction 
Mastocytosis (OMIM 154800) is a group of disorders which have in common abnormal 
accumulation of mast cells in different organs and apparatuses, including the skin, bone 
marrow, gastrointestinal tract, spleen, liver, and lymph nodes. According to the World 
Health Organization (WHO) classification, based on clinical, biochemical and pathological 
criteria [Valent et al., 2001; Sánchez-Muñoz et al., 2011], seven variants of mastocytosis 
are defined: cutaneous mastocytosis (in which mast cell infiltration is limited to the skin), 
extracutaneous mastocytoma, indolent systemic mastocytosis, aggressive systemic 
mastocytosis, systemic mastocytosis associated with other clonal hematological non-mast 
cell lineage disease, mast cell leukemia, and mast cell sarcoma [Valent et al., 2001]. 
The skin is the organ most commonly involved, and especially in children, is usually the 
only organ affected [Carter et al., in Fitzpatrick’s 7th edition]. There are four types of 
cutaneous mastocytosis: a) maculopapular type (formerly: urticaria pigmentosa), b) 
mastocytoma, c) diffuse cutaneous mastocytosis, and d) telangiectasia macularis eruptiva 
perstans. The first two variants are the most common, accounting for around 85 and 10 per 
cent of cases of cutaneous mastocytoses, respectively [Lange et al., 2011]. Classic clinical 
manifestations of both these major types of cutaneous mastocytosis include a single 
brownish nodule (in case of mastocytoma), or a number of brownish, yellow-tan or reddish-
brown macules, papules or plaques (in case of urticaria pigmentosa), usually located on the 
trunk and extremities. These lesions usually urticate and may also blister with rubbing; this 
reaction is known as Darier’s sign. Other clinical features such as flushing, urticaria, 
headache, diarrhea and abdominal pain, caused by the excessive production of mast cell-
dependent mediators, such as histamine, may also be present. 
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Cutaneous mastocytosis are divided into two groups based on the age of onset. The first 
group encompasses the most part of cases, which occur in pediatric age and usually 
disappear by adolescence. The second group of patients has adult-onset disease, which 
typically persists or progresses and may involve other organs (systemic mastocytosis). 
However, distinction is not always clear, and some cases of early onset disease may persist 
or have systemic involvement [Caplan, 1963; Kettelhut et al., 1991]. 
The cause of cutaneous mastocytosis is unknown, but somatic mutations in the KIT gene has 
been related to this disease. The KIT gene encodes for the tyrosine kinase receptor KIT, and 
it is physiologically activated by its ligand, the stem cell factor (SCF), which plays a key 
role in mast cell proliferation. According to this, mast cell hyperplasia, which is the key 
pathological feature of mastocytosis, is usually caused by gain-of-function KIT mutations, 
which lead to the constitutive activation of the receptor (Figure 1) [Longley et al., 1996; 
Yang et al., 2010].  
Somatic KIT mutations, including the common mutations in the codon 816, have been found 
in the skin lesions of the most part of adult patients with sporadic mastocytosis [Longley et 
al., 1999; Yanagihori et al., 2005]. In contrast, only recently, it has been consistently proved 
that somatic KIT mutations are also common in sporadic childhood-onset mastocytosis 
[Yanagihori et al., 2005; Bodemer et al., 2010], while the role of KIT in familial 
mastocytosis still remains unclear [Rosbotham et al., 1999; Bodemer et al., 2010; Wöhrl et 
al., 2013].  
Familial cutaneous mastocytosis is a very rare condition; nevertheless, it is being reported 
with increased frequency during the last decades [Fett et al., 2013]. The aim of our study is 
to report the familial cases of mastocytosis examined in our Dermatology Unit since 1990, 
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and to shed some more light on the pathogenesis of the disease by searching for germ-line 
KIT mutations in our patients with familial cutaneous mastocytosis. 
 
 
 
 
Figure 1. Schematic representation of KIT protein and location of KIT gene mutations 
described previously. The mutation at codon 560 (exon 11), which is within the 
juxtamembrane domain, and the mutations at codon 816/820 (exon 17), which are within 
the second catalytic domain, cause ligand-independent autophosphorylation of KIT receptor 
protein. In contrast, the mutation at codon 839 (exon 18, not investigated in the present 
work) results in loss of receptor function [Yanagihori et al., 2005]. The Met541Leu 
polymorphic variant is within the transmembrane domain (not shown), and seems to confer 
an enhanced proliferative response to low levels of its ligand, the stem cell factor [Foster et 
al., 2008]. The illustration is from Yanagihori et al., 2005. 
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PATIENTS AND METHODS 
Patients 
The inpatient clinical records of the Pediatric Dermatology Unit of the University of Milan 
have been reviewed in order to identify familial cases of cutaneous mastocytosis over a 22 
year period (1990-2012). Overall, ten families with at least two patients with cutaneous 
mastocytosis have been identified. Subsequently, patients were contacted by telephone and 
asked to participate in our study. Finally, a total of 18 patients, members of seven families, 
accepted to be available for an interview, physical examination, clinical photographs, and a 
venous blood sample for genetic analysis. All adult patients gave written informed consent 
and parents gave consent for their children prior to enrolment in the study.  
 
DNA extraction from human polymorphonuclear neutrophils.  
Human polymorphonuclear neutrophils (PMNs) were separated from whole blood by using 
the Polymorphprep
TM
 solution (Axis-Shield, prod. No. 1114683; www.axis-shield.com). 
Then, genomic DNA (gDNA) was isolated from PMNs by using the DNAzol Reagent 
(Invitrogen Life Technologies, Cat. No. 10503-027; www.invitrogen.com) according to the 
manufacturer’s instructions. Briefly, PMNs were lysed in DNAzol Reagent and gDNA 
was precipitated with 100% ethanol. Subsequently, after two 75% ethanol washes, gDNA 
was solubilized in water and stored at 4°C.  
 
Screening of mutations in the KIT gene. 
The presence of mutations in the exons 10 and 11 of the KIT gene (NCBI Reference 
Sequence: NG_007456) was investigated using direct sequencing, whereas the presence of 
P a g e  | 6 
 
 
 
mutations in the exon 17 of the KIT gene was investigated using direct sequencing and two 
other more sensitive assays: the HinfI assay and the amplification refractory mutation 
system (ARMS) polymerase chain reaction (PCR) for the Asp816Val and Asp816Tyr 
mutation, respectively.  
The primer pairs 10A [5’-GATCCCATCCTGCCAAAGT-3’ (forward)] and 10B [5’-
ATTGTCTCAGTCATTAGAGCAC-3’ (reverse)] (annealing temperature: 60°C), 11A [5’-
CAGGTAACCATTTATTTGT-3’ (forward)] and 11B [5’- TCATTGTTTCAGGTGGAAC-
3’ (reverse)] (annealing temperature: 54°C), and 17A [5’-AGTTTTCACTCTTTACAAG-3’ 
(forward)] and 17B [5’- TGTCAAGCAGAGAAATGGGT-3’ (reverse)] (annealing 
temperature: 53°C) were used to obtain PCR products of 206 base pairs (bp), 327 bp and 
212 bp, which contain the exons 10, 11 and 17 of the KIT gene, respectively. Subsequently, 
each PCR product was sequenced using the Applied Biosystems BigDye Terminator v1.1 
Cycle Sequencing Kit (Applied Biosystems; www.lifetechnologies.com) and the Applied 
Biosystems 16-capillary 3130xl Genetic Analyzer (Applied Biosystems).  
For the screening of the c.2447A>T (p.Asp816Val) mutation in the KIT gene, we also used 
the HinfI (from Haemophilus Influenzae) restriction enzyme assay. Briefly, the 212-bp PCR 
product containing the exon 17 of the KIT gene was digested with HinfI, which recognizes 
the 5’-G|ANTC-3’ sequence. In case of wild-type sequence, the digestion gives rise to a 161 
bp fragment, but when an A>T transition is present at position 2447 of the coding sequence 
of the KIT gene (ENST00000288135), an additional HinfI site is created leading to a 147 bp 
DNA fragment [Beghini et al., 2000].  
Finally, for the screening of the c.2446G>T (p.Asp816Tyr) mutation, we also used the 
ARMS PCR. Briefly, 167 (wild-type) and 168 (mutated) ARMS PCR products of the exon 
17 of the KIT gene were generated using the forward 17A primer 5’-
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AGTTTTCACTCTTTACAAG-3’ and the following fluorescently labeled reverse primers: 
17B-Fam-wt 5’-TAGAATCATTCTTGATGTC-3’ for the wild-type allele, and 17B-Hex-
Tyr 5’-TTAGAATCATTCTTGATGTA-3’ for the mutated allele. The PCR programs 
consisted of an initial denaturation step at 94°C for 5 min, followed by 33 cycles at 94°C for 
30 s, 52°C for 15 s and 72°C for 15 sec, and a final extension step at 72°C for 10 min. The 
PCR products were resolved on 2% agarose-gel and visualized using a Typhoon 9200 
Imager system (GE Healthcare Life Sciences; www.gelifesciences.com) [Beghini et al., 
2004]. 
 
RESULTS 
Clinical features of the patients with familial cutaneous mastocytosis. 
A total of 18 patients, members of seven unrelated families, agreed to participate in this 
study. More specifically, we studied 14 females and 4 males (F/M ratio: 3.5:1) with familial 
mastocytosis. The mean age at onset was 5.4 years, with range from 0 (at birth) to 22 years. 
Fourteen out of 18 patients were affected by urticaria pigmentosa at the time of diagnosis, 
two subjects (F3-II:3 and F6-I:1) had no clinical manifestations at that time, but a history of 
urticaria pigmentosa, and another two cases, part of the same family (F1-II:1 and F1-II:2), 
had a solitary mastocytoma. Not all family members had undergone skin biopsy, but at least 
one member of each family had a previous histological confirmation of cutaneous 
mastocytosis. 
The main clinical data of these 18 patients are reported in Table 1, the family pedigrees are 
illustrated in Figure 2, while images representing examples of clinical and histopathological 
features are shown in Figures 3 and 4, respectively. 
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The first family consisted of:  
Patient 1 (F1-II:3) 
A 18-year-old woman, sister of the patients 2 e 3, who was diagnosed with cutaneous 
mastocytosis at the age of 9 years. She had frequent headaches and episodes of flushing. A 
few years earlier, she had an episode of angioedema with laryngeal involvement and airway 
obstruction, but the precise cause was unknown. Physical examination revealed two reddish 
brown macules on the abdomen. Darier’s sign was positive, and dermographic urticaria was 
present. Serum tryptase level was < 20 ng/mL, routine blood analysis and total blood levels 
of IgE were normal. Both chest X-ray and abdominal ultrasound showed no evidence of 
systemic involvement. 
 
Patient 2 (F1-II:2) 
The 20-year-old sister of patients 1 e 3, who had a tan plaque on her trunk at birth. This 
lesion has been stable over time. As her sister, she had frequent headaches and episodes of 
flushing. She also suffered from allergic rhinitis due to ambrosia artemisiifolia and grass 
pollen, as well as from atopic dermatitis. Physical examination revealed a large light brown 
urticating plaque on her lower abdomen. Darier’s sign was positive, and dermographic 
urticaria was present. Abdominal ultrasound revealed a slightly enlarged retroperitoneal 
lymph node but no organomegaly. Serum tryptase level was < 20 ng/mL. Routine blood 
analysis and total blood levels of IgE were normal.  
 
Patient 3 (F1-II:1) 
The 22-year-old brother of patients 1 e 2, who had had a solitary, large brown plaque on the 
abdomen since the age of 10 years. Darier’s sign was positive. Past medical history included 
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also allergic rhinitis and asthma since childhood. Serum tryptase level was < 20 ng/mL. 
Routine blood analysis, chest X-ray and abdominal ultrasound were normal. 
 
The second family was composed of: 
Patient 4 (F2-II:1) 
A 5-year-old girl, daughter of patient 5, who began developing tan lesions over the trunk at 
3 years of age. She had no associated manifestations. Physical examination revealed 
numerous light brown maculopapular lesions and patches on the trunk and neck. Darier’s 
sign was positive. No systemic manifestations were detected. 
 
Patient 5 (F2-I:2) 
A 35-year-old woman, mother of patient 4, who was diagnosed with urticaria pigmentosa at 
the age of 8. She presented with a few light brown macules on her abdomen and neck with 
edges being not completely sharp. Darier’s sign was positive. No organomegaly or 
lymphadenopathy was appreciated. Skin biopsy revealed sheets of mast cells in the dermis 
in hematoxylin and eosin (see Figure 4), better demonstrated by the use of Giemsa stain. 
Serum tryptase level was < 20 ng/mL, routine blood analysis and total blood levels of 
immunoglobulin E (IgE) were normal. 
 
The third family consisted of: 
Patient 6 (F3-III:2) 
A 7-year-old girl, daughter of patient 7, who began developing tan skin lesions on the trunk, 
neck and scalp, starting at 4 years of age. Examination disclosed eight yellowish brown 
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maculopapules involving the anatomical areas mentioned above. Darier’s sign was positive. 
No organomegaly or lymphadenopathy was appreciated. 
 
Patient 7 (F3-II:1) 
A 36-year-old woman, mother of patient 6, who was diagnosed with cutaneous mastocytosis 
at the age of 6. She recalled having an episode of anaphylaxis after appendectomy at the age 
of 10 years. In addition, she had had some episodes of generalized pruritus before, mainly 
after exposure to excessive heat. She presented with four reddish-brown urticating macules 
on her trunk. Darier’s sign was positive. The liver, the spleen and the lymph nodes were not 
clinically enlarged. 
 
Patient 8 (F3-II:3) 
A 39-year-old woman, sister of patient 7 and mother of patient 9, who began to have tan 
macules around her neck and on her scalp when she was 10 years old. She noted gradual 
fading of these lesions until complete clearing during her late 20s. She suffered from 
allergic contact dermatitis due to thimerosal. Examination showed dermographic urticaria 
but no skin lesions suggestive of mastocytosis. No systemic manifestations were identified. 
 
Patient 9 (F3-III:4) 
A 9-year-old girl, daughter of patient 8, who began to have cutaneous tan lesions at the age 
of 5 years. Physical examination revealed a few yellowish brown maculopapules on the 
trunk and neck. Darier’s sign was positive. Clinical examination revealed a soft abdomen 
with no organomegaly. There was no lymphadenopathy. As her mother, she presented 
dermographic urticaria. 
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The fourth family consisted of: 
Patient 10 (F4-II:1) 
A 2-year-old boy, monozygotic twin of the patient 11, who began developing large patches 
on his trunk and arms at 2 months of age. He presented with about a dozen light brown 
patches located on his trunk, thigh, forearm, neck and face. Darier’s sign was positive. 
Physical examination was otherwise normal. Two months before, he had an acute episode of 
urticaria but the precise cause was unknown. In the past he had also developed a 
morbilliform rash after taking an oral cephalosporin (cefpodoxine). Blood tests were 
unremarkable except for elevated blood levels of IgE (= 90 kUA/I, normal values  30). The 
parents were not consanguineous and there was not family history of mastocytosis.  
 
Patient 11 (F4-II:2) 
A 2-year-old boy, monozygotic twin of the patient 10, who developed two yellowish brown 
patches, one on his trunk and one on the neck, at 5 months of age. Since then, these lesions 
have remained unchanged. Darier’s sign was positive. He had no associated systemic 
manifestations. As with his twin brother, blood analyses showed raised blood levels of IgE 
(= 100 kUA/I, normal values  30). 
 
The fifth family consisted of: 
Patient 12 (F5-II:2) 
A 15-year-old boy, son of the patient 13, who developed tan papules on his trunk at 3 years 
of age. The number of lesions progressively increased over time. In fact, physical 
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examination revealed numerous small sized macules on the trunk. Darier’s sign was 
negative. There was no evidence of internal lesions. 
 
Patient 13 (F5-I:2) 
The 47-year-old mother of patient 12, who was diagnosed with cutaneous mastocytosis at 
the age of 11 years. At the age of 30, after the birth of her first son, the skin lesions had 
cleared except for one on her trunk. Indeed, she presented with a brown patch next to her 
left shoulder. Darier’s sign was positive and she had dermographic urticaria. No 
visceromegaly or lymphadenopathy was appreciated. 
 
The sixth family consisted of: 
Patient 14 (F6-III:1) 
A 7-year-old girl, daughter of the patient 15, who began developing tan skin lesions on her 
trunk and neck at 3 years of age. She had frequent headaches and episodes of flushing. 
Physical examination revealed numerous reddish brown urticating papules and about a 
dozen similar plaques. Darier’s sign was positive and she had dermographic urticaria. The 
remainder of the physical examination was unremarkable. 
 
Patient 15 (F6-II:2) 
The 32-year-old mother of patient 14 and daughter of patient 16, who first developed 
slightly itchy pigmented lesions on the trunk at 4 years of age. These lesions were numerous 
until the age of 20, when she had her first pregnancy. After that, the majority of these 
lesions were spontaneously cleared. Like her daughter, she suffered from frequent 
headaches and episodes of flushing. Physical examination showed nearly a dozen brown 
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macules on the trunk. Darier’s sign was positive and she had dermographic urticaria. No 
organomegaly or lymphadenopathy was appreciated. 
 
Patient 16 (F6-I:1) 
The 56-year-old mother of patient 15 and grandmother of patient 14, who began developing 
tan macules on the trunk and neck during her first pregnancy, at the age of 22 years. Two 
years after, she noted gradual fading of these lesions until complete clearing. A few years 
later, she had two other pregnancies which did not lead to recurrence of the disease. 
Physical examination was unremarkable. 
 
The seventh family consisted of: 
Patient 17 (F7-II:3) 
A 7-year-old girl, sister of patient 18, who began developing small tan skin lesions on the 
trunk, neck and upper limbs at 8 months of age. These lesions tended to increase in number 
over time. At the age of 6 years, she had an episode of acute urticaria related to ingestion of 
shrimp. Physical examination revealed numerous light brown maculopapular lesions on the 
trunk, neck and arms, as well as three larger, light brown patches on the trunk. Darier’s sign 
was positive. No systemic manifestations were detected. 
 
Patient 18 (F7-II:2) 
The 11-year-old sister of patient 17, who had three tan lesions on the trunk and on the neck 
at birth. These lesions have been quite stable over time, except for slight fading in the last 
years. Past medical history included skin rash caused by oral amoxicillin/clavulanic acid 
and an episode of urticaria “after the use of a colored soap”. Physical examination revealed 
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three faint reddish brown patches, one on the neck and two on the trunk. Darier’s sign was 
negative, but her parents reported that in the past, these lesions used to become red and 
swollen after rubbing. No organomegaly or lymphadenopathy was appreciated. 
 
Table 1. Clinical data regarding the 18 patients with familial cutaneous mastocytosis 
followed in our department. 
Patient 
Age 
(years)/sex 
Age at 
onset 
Extent of 
lesions 
Lesion sites 
Systemic 
involvement 
Disease 
evolution 
1 18/F 8 years 2 macules trunk 
(flushing, 
headaches) 
stable 
2 20/F birth 1 patch trunk 
(flushing, 
headaches) 
stable 
3 22/M 10 years 1 plaque trunk no stable 
4 5/F 3 years ~100 macules neck, trunk no stable 
5 35/F 8 years 4 macules neck, trunk no improved 
6 7/F 4 years 
8 
maculopapules 
neck, scalp, 
trunk 
no stable 
7 36/F 6 years 4 macules trunk 
(pruritus, 1 
anaphylaxis) 
improved 
8 39/F 10 years 0 - no improved 
9 9/F 5 years 
7 
maculopapules 
neck, trunk no stable 
10 2/M 
2 
months 
9 patches 
trunk, 
forearm, 
thigh, neck, 
face 
no stable 
11 2/M 
5 
months 
2 patches trunk, neck no stable 
12 15/M 3 years >200 macules trunk no worsened 
13 47/F 11 years 1 patch trunk no improved 
14 7/F 3 years 
>200 papules+ 
plaques  
trunk 
(flushing, 
headaches) 
worsened 
15 32/F 4 years ~15 macules trunk 
(flushing, 
headaches) 
improved 
16 56/F 22 years 0 trunk, neck no improved 
17 7/F 
8 
months 
~200 macules 
trunk, arms, 
neck 
no worsened 
18 11/F birth 3 patches trunk, neck no improved 
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Figure 2. Pedigrees of the seven families in which more than one member had 
cutaneous mastocytosis. Subjects investigated for the single nucleotide polymorphism 
(SNP) A1621C (rs3822214) in the KIT gene, resulting in a Met541Leu substitution, are 
indicated with an asterisk; red asterisk = presence of the SNP; black asterisk = absence of 
the SNP. 
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Figure 3. Clinical features of four patients with familial cutaneous mastocytosis. A: 
numerous tan macules and patches on the abdomen of patient 14; B: solitary reddish brown 
plaque on the suprapubic area of patient 2; C: a few yellowish brown maculopapules on the 
neck of patient 9; D: light brown patches on the back of patient 4.  
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Figure 4. Histopathological features of two patients with familial cutaneous 
mastocytosis. A, B: histopathological examination of a skin biopsy from the abdominal skin 
of patient 5 revealed excessive numbers of mast cells in the dermis (hematoxylin and eosin 
stain, original magnification ×100 and ×400, respectively). In patient 15, mast cells were 
strongly positive with Giemsa stain and they were localized mainly around blood vessels 
(C: original magnification ×100). At high magnification, these cells showed purple granules 
in the cytoplasm (D: original magnification ×400). 
 
Results of the molecular analyses  
No mutation in the exons 10, 11 and 17 of the KIT gene, encompassing the amino-acids 
514-549, 550-592, and 788-828, respectively, was identified by direct sequencing of the 
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DNA isolated from PMNs of all the subjects with familial cutaneous mastocytosis 
investigated in this study. In addition, as shown in Figures 5 and 6, the gain-of-function 
p.Asp816Val (p.D816V) and p.Asp816Tyr (p.D816Y) mutations were not identified by 
using the more sensitive HinfI restriction enzyme and ARMS PCR assays, respectively, in 
the subjects investigated from six out of the seven families. 
Notably, in 13 out of 16 affected (~80%) members of the six families investigated, we found 
the single nucleotide polymorphism (SNP) A1621C (rs3822214) in the exon 10 of the KIT 
gene (ENST00000288135), resulting in a Met541Leu substitution. This variant was also 
found in three unaffected family members (F3-I:1, F4-I:2, and F5-I:1) and it was absent in 
three affected subjects (F3-II:3, F5-I:2, and F6-I:1) (see Figure 2 and Table 2 for further 
details) (p = 0.2829, not significant; Fisher’s exact test). 
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Figure 5. HinfI restriction enzyme assay for detection of the Asp816Val (D816V) 
mutation in the KIT gene. The digestion of the 212 base-pair (bp) polymerase chain 
reaction (PCR) product encompassing the exon 17 of the KIT gene gives rise to a 161 bp 
fragment in all the investigated patients, including a normal subject (C); no additional 
fragment of 147 bp was observed, thus confirming the lack of the gain-of-function 
Asp816Val (D816V) mutation in all the cases. The members of each family investigated by 
HinfI assay are indicated as in the pedigrees of the Figure 2. No subject from Family 7 was 
investigated by HinfI assay. F1-6: Family 1-6.  
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Figure 6. Amplification refractory mutation system (ARMS) polymerase chain 
reaction (PCR) for detection of the Asp816Tyr (D816Y) mutation in the KIT gene. The 
167 base-pair wild-type PCR product is present in all the investigated subjects, whereas no 
168 base-pair PCR product was obtained by using the fluorescently labeled reverse primer 
17B-Hex-Tyr 5’-TTAGAATCATTCTTGATGTA-3’ for the mutated allele, thus confirming 
the lack of the gain-of-function Asp816Tyr (D816Y) mutation in all the cases. The members 
of each family investigated by ARMS PCR are indicated as in the pedigrees of the Figure 2. 
No subject from Family 7 was investigated by ARMS PCR. F1-6: Family 1-6. 
 
P a g e  | 21 
 
 
 
Table 2. Distribution of the p.Met541Leu (p.M541L) polymorphism in the exon 10 of 
the KIT gene in subjects from the families with familial cutaneous mastocystosis. The 
members of each family are indicated as in the pedigrees of the Figure 2. 
 
Subject Sex Clinical phenotype p.Met541Leu (p.M541L) 
F1-I:2 F Unaffected negative 
F1-II:1 M Affected +ve 
F1-II:2 F Affected +ve 
F1-II:3 F Affected +ve 
F2-I:2 F Affected +ve 
F2-II:1 F Affected +ve 
F3-I:1 M Unaffected +ve 
F3-II:1 F Affected +ve 
F3-II:2 M Unaffected negative 
F3-II:3 F Affected negative 
F3-III:2 F Affected +ve 
F3-III:4 F Affected +ve 
F4-I:1 M Unaffected negative 
F4-I:2 F Unaffected +ve 
F4-II:1 M Affected +ve 
F4-II:2 M Affected +ve 
F5-I:1 M Unaffected +ve 
F5-I:2 F Affected negative 
F5-II:2 M Affected +ve 
F6-I:1 F Affected negative 
F6-II:2 F Affected +ve 
F6-III:1 F Affected +ve 
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Discussion 
Cutaneous mastocytosis is an uncommon disease, and usually occurs sporadically [Feger et 
al., 2004]. Different somatic mutations (screened from cutaneous lesions) in KIT gene, most 
frequently at position D816, have been associated with the development of the disease, in 
both pediatric and adult sporadic cases [Yanagihori et al., 2005; Bodemer et al., 2010; 
Kambe et al., 2010]. 
Familial cases of cutaneous mastocytosis have been rarely described, and only a few 
families have been studied genetically [Zanotti et al., 2013; Fett et al., 2013]. 
In the present work, we reported the largest series of familial cases with cutaneous 
mastocytosis, and we investigated the possible contribution of germ-line KIT mutations or 
polymorphic variants in the development of the disease. More specifically, we observed 18 
patients, part of seven unrelated families, with no systemic manifestation other than some 
features caused by the excess production of mast cell-dependent mediators (e.g. episodes of 
flushing and headache). 
Fourteen out of 18 patients (F/M ratio: 3.5:1) with familial cutaneous mastocytosis were 
female, and this female preponderance has been noted in previous reports [Fowler et al., 
1986; Anstey et al., 1991], but the numbers are too small for statistical significance. 
Mean follow-up was 15.1 (range 2-36) years. During this period of time, the clinical 
behavior of the disease was variable. In particular, seven out of 18 patients had an 
improvement over time, eight were stable, and three experienced a progressive worsening of 
cutaneous mastocytosis. Of note, among the six women who have been pregnant at least 
once, three experienced important clinical changes during pregnancy: two of them had a 
dramatic improvement (F5-I:2 and F6-II:2), while another subject (F6-I:1) experienced the 
onset of the disease.  
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The pattern of inheritance in our families (see pedigree in Figure 2) is compatible with an 
autosomal dominant trait with incomplete penetrance, as previously suggested [Anstey et 
al., 1991]. Although sporadic cases of cutaneous mastocytosis have been related to somatic 
mutations in the KIT gene, no germ-line KIT mutation in the exon 10, 11 and 17 (which are 
the hotspot mutation regions of KIT gene) was found in any of the affected subjects.  
To our knowledge, only one family with a novel, activating germ-line KIT mutation in the 
exon 17 (p. N8222I) suffering from urticaria pigmentosa (not associated with other 
diseases) has been reported so far [Wasag et al., 2011]. In contrast, no germ-line KIT 
mutation (screened from blood samples) was found in the familial cases investigated by 
Rosbotham et al. in 1999, Sato-Matsumura et al. in 1999, Bodemer et al. in 2009, and 
Wöhrl et al. in 2013. In other familial cases, a germ-line KIT mutation was found, indeed, 
but the picture was more complex because of the co-presence of a gastrointestinal stromal 
tumor [Beghini et al., 2001; Hartmann et al., 2005], or the presence of more severe forms of 
mastocytosis [Tang et al., 2004; Zhang et al., 2006]. 
Although the entire coding region of the KIT gene was not investigated, the lack of germ-
line mutations in the most commonly affected exons of the KIT gene provides conclusive 
evidence that distinct factors are involved in familial cutaneous mastocytoses. 
Polymorphisms of KIT, IL4-receptor [Daley et al., 2001] or mast cell growth factors might 
be taken into account for explaining the variety of cutaneous mastocytosis. In particular, as 
suggested by Foster et al. [2008], the presence of the polymorphism M541L in the 
transmembrane domain of the KIT gene can be a predisposing factor to the disease, because 
- in our cohort - it was found in the majority of affected subjects (13 out of 16) from all the 
families investigated, whereas its frequency in healthy individuals is 0.05-0.12 according to 
the 1000 Genomes Project data (i.e., in healthy population, it is present at a frequency of 5-
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12 per 100 individuals). Indeed, mast cells expressing the M541L KIT may have a 
proliferative and/or a survival advantage, as demonstrated in vitro by Foster et al. [2008]. It 
should be stressed, however, that the M541L KIT seems to be neither sufficient nor 
necessary to cause mastocytosis, because in our series of familial cutaneous mastocystosis it 
was found in unaffected family members, and it was absent in affected family members. Our 
data should be carefully verified, as pre-analytical biases (including sampling errors – see 
for example the segregation of the polymorphism in the case of family 3) cannot be ruled 
out a priori, but the presence of the M541L KIT in unaffected family members was also 
noted by Foster et al. [2008]. 
In our series, screening for mutations in the KIT gene was not performed on skin biopsy 
samples, given the lack of proper material for genetic analyses. Therefore, we were unable 
to verify whether somatic mutations in the KIT gene commonly occur also in familial cases 
of cutaneous mastocytosis. The gain-of-function D816V KIT mutation was found in the skin 
lesions of 2 out of 4 subjects with familial cutaneous mastocytosis by Bodemer et al. [2009] 
suggesting that somatic KIT mutations may play a key role in familial cases of cutaneous 
mastocytosis, as well as in sporadic cases. However, no KIT mutation was found in skin 
lesions of three subjects with familial cutaneous mastocystosis reported by Longley et al. 
[1999] and in the proband of the family with urticaria pigmentosa reported by Rosbotham et 
al. [1999]. 
Given the presence of the above-mentioned uncertainties, future studies regarding familial 
cases of cutaneous mastocytosis, including complete sequencing of the KIT gene, genetic 
analyses on skin biopsy samples, and exome sequencing might allow the identification of 
new molecular determinants of cutaneous mastocytosis. 
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